A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or > 100 cells/mm3.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
HIV infection with CD4 counts = or > 100 cells/mm3.
Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years.
History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.
Patients with the following symptoms and conditions are excluded:
Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy.
Systemic antiherpes medication.
Patients with the following prior conditions are excluded: